How long is the resistance to entrectinib/Luo Shengquan?

Entrectinib (Entrectinib), as an oral targeted drug, plays an important role in the field of precision tumor treatment. Its main targets are NTRK gene fusion and abnormal signaling pathways such as ROS1 and ALK. Such mutations have been found in some rare tumors and non-small cell lung cancer. Because it can directly act on driver genes and block cancer cell proliferation signals, it is considered an efficient and precise personalized medicine. However, a common concern among patients during use is "how long does resistance last", that is, how long the drug can maintain its efficacy, which determines treatment planning and subsequent drug selection.

The development of drug resistance is a common challenge in cancer treatment and is not limited to entrectinib. In the process of continuous division and evolution, cancer cells may gradually escape their original inhibitory effects through mechanisms such as new mutations, activation of bypass pathways, or drug efflux. Therefore, the resistance time to entrectinib is not fixed, but varies from person to person and is affected by multiple factors. Generally speaking, judging from internationally published clinical data and real-world experience, some patients progress within a few months, while others can maintain stable conditions for a year or even longer.

Once resistance to entrectinib occurs, it does not mean that there is no way out for treatment. Part of the resistance mechanisms have been revealed in research, such as target changes caused by secondary mutations, which provide directions for the subsequent development of new generation inhibitors or combination treatments. In clinical practice, doctors will consider switching to other similar targeted drugs, immunotherapy or chemotherapy regimens based on changes in the patient's condition to prolong overall survival time. In addition, molecular testing is particularly important in this process. Through genetic testing after drug resistance, the specific mutation type can be clarified, thereby providing a basis for second-line or even third-line treatment selection.

In terms of price and accessibility, entrectinib has been included in the medical insurance reimbursement list. For eligible patients, it can significantly reduce the financial burden and enable the drug to be continuously used, thereby indirectly extending the effective treatment period before drug resistance.

Reference materials:https://www.roche.com/products/rozlytrek